Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Benjamin Scirica MD

Benjamin Morgan Scirica MD

Senior Physician and Director, Innovation, Cardiovascular Division, Brigham and Women's Hospital; Professor of Medicine, Harvard Medical School; Senior Investigator, TIMI Study Group, Boston, Massachusetts

Dr. Benjamin Scirica is a senior physician and Director of Innovation in the Cardiovascular Division at Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School. He is a Senior Investigator at the TIMI Study Group (an academic research organization based at Brigham and Women's Hospital that has performed over 75 clinical trials in cardiometabolic diseases).

His research interests center on the risk stratification, management, and the identifation of novel therapies to improve outcomes in patients with acute coronary syndromes and cardiometabolic disorders. 

Dr. Scirica has authored or co-authored over 200 peer-reviewed articles and is a reviewer for multiple journals, including The New England Journal of Medicine, JAMA, The Lancet, Circulation, and Journal of the American College of Cardiology (JACC).

Disclosures

  • Institutional research support to Brigham and Women’s Hospital from: Amgen; Better Therapeutics; Boehringer Ingelheim; Merck; Novo Nordisk; Pfizer; Verve Therapeutics
  • Consulting fees from: AbbVie (DSMB); Amgen; AstraZeneca (DSMB); Bayer; Boehringer Ingelheim (DSMB); Elsevier Practice Update Cardiology; Hanmi (DSMB); Lexeo (DSMB); Novo Nordisk; Verve Therapeutics; and equity in Health [at] Scale; Arboretum Lifescience

Recent Contributions to PracticeUpdate:

  1. Effect of Alirocumab on Mortality After Acute Coronary Syndromes
  2. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease
  3. Metformin Associated With Reduced Left Ventricular Hypertrophy in Patients With Coronary Artery Disease
  4. Canagliflozin Reduces Heart Failure Events Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes
  5. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Prior Myocardial Infarction
  6. 24-Hour Blood Pressure–Lowering Effect of an SGLT2 Inhibitor in Patients With Diabetes and Hypertension
  7. 2018 Top Stories in Cardiology: Cardiovascular Outcome Studies: REDUCE-IT
  8. Lorcaserin and Renal Outcomes in Obese and Overweight Patients
  9. Variable Use of Targeted Temperature Management in Out-of-Hospital Cardiac Arrest
  10. AHA Scientific Sessions 2018: Recommendations From Dr. Ben Scirica

Most Read This Week

Recently Updated